TY - JOUR
T1 - Antibody-drug conjugates
T2 - The new generation of biotechnological therapies against cancer
AU - Melgarejo-Rubio, Guadalupe
AU - Pérez-Tapia, Sonia M.
AU - Medina-Rivero, Emilio
AU - Velasco-Velázquez, Marco A.
N1 - Publisher Copyright:
© 2020 Academia Nacional de Medicina. All rights reserved.
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Therapeutic antibodies are recombinant proteins used in the treatment of cancer. There is a new generation of monoclonal antibodies with activity against cancer cells, known as antibody-drug conjugates. These molecules are made up of three elements: a monoclonal antibody, a highly potent cytotoxic drug, and a chemical linker that binds them together. The antibody recognizes tumor antigens, thereby allowing targeted delivery of the cytotoxic agent to cancer cells. After recognizing its antigen, the antibody-drug conjugate is endocytosed by the target cells, where the protein fraction is degraded into lysosomes, releasing the cytotoxic drug. This article reviews antibody-drug conjugates general characteristics and describes the clinical evidence of efficacy and safety of the first four approved by regulatory agencies in the United States and Europe.
AB - Therapeutic antibodies are recombinant proteins used in the treatment of cancer. There is a new generation of monoclonal antibodies with activity against cancer cells, known as antibody-drug conjugates. These molecules are made up of three elements: a monoclonal antibody, a highly potent cytotoxic drug, and a chemical linker that binds them together. The antibody recognizes tumor antigens, thereby allowing targeted delivery of the cytotoxic agent to cancer cells. After recognizing its antigen, the antibody-drug conjugate is endocytosed by the target cells, where the protein fraction is degraded into lysosomes, releasing the cytotoxic drug. This article reviews antibody-drug conjugates general characteristics and describes the clinical evidence of efficacy and safety of the first four approved by regulatory agencies in the United States and Europe.
KW - Antibody-drug conjugates
KW - Brentuximab vedotin
KW - Gemtuzumab ozogamicin
KW - Inotuzumab ozogamicin
KW - Trastuzumab emtansine
UR - http://www.scopus.com/inward/record.url?scp=85086531398&partnerID=8YFLogxK
U2 - 10.24875/GMM.M20000388
DO - 10.24875/GMM.M20000388
M3 - Artículo de revisión
C2 - 32538994
SN - 0016-3813
VL - 156
SP - 228
EP - 235
JO - Gaceta Medica de Mexico
JF - Gaceta Medica de Mexico
IS - 3
ER -